Dengue in Europe in 2026: from tropical postcard to local outbreak

For decades, Europeans associated dengue fever with faraway tropical destinations. That perception is now dangerously outdated. Between 2022 and 2024, the number of locally acquired dengue cases on the European mainland rose from 71 to 304, according to the European Centre for Disease Prevention and Control (ECDC). France, Spain, and Italy are at the epicentre of this shift, and epidemiologists warn that the trend will only accelerate as climate conditions continue to favour the disease's primary vector: the Asian tiger mosquito.

This article explains where dengue is spreading in Europe, what the symptoms look like, who is most at risk, and -- most importantly -- what you can do about it right now.

What Is Dengue Fever?

Dengue is a viral infection transmitted to humans through the bite of infected Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus. According to the World Health Organization (WHO), the number of cases reported to WHO rose from 505,430 in 2000 to 14.6 million in 2024.

The virus has four distinct serotypes (DENV-1 through DENV-4). Infection with one serotype provides lifelong immunity to that specific strain but only short-term cross-protection against the others. A second infection with a different serotype can increase the risk of severe dengue, a potentially life-threatening complication.

The Rise of Autochthonous Dengue in Europe

The term "autochthonous" means locally acquired -- in other words, the person was bitten by an infected mosquito within Europe itself, not during travel abroad. This distinction matters enormously for public health planning.

France: The Frontline

France has become Europe's dengue hotspot. In 2024, the country reported 83 locally acquired dengue cases across Alpes-Maritimes, Drôme, Hérault, Pyrénées-Orientales or Lozère, Vaucluse, and Var, according to ECDC. Southern France's Mediterranean climate provides ideal breeding conditions for Aedes albopictus, and the dense urban population enables rapid transmission cycles.

Spain: A New Front Opens

Spain reported its first significant cluster of locally acquired dengue in 2024, with 8 cases in the Catalonia region, according to ECDC. Prior to this, autochthonous dengue in Spain was essentially unheard of. The Iberian Peninsula's warm climate and expanding mosquito populations suggest this will not be a one-off event.

Italy: Sustained Local Transmission

Italy reported 213 locally acquired dengue cases in 2024, across Abruzzo, Emilia-Romagna, Lombardy, the Marches, Tuscany, and Veneto, according to ECDC. Italy has a long history of Aedes albopictus establishment -- the tiger mosquito was first detected in the country in 1990 -- and its dense populations in the Po Valley and along the Adriatic coast create persistent transmission risk.

The Trajectory: 71 to 304 in Two Years

In 2022, the EU/EEA recorded 71 locally acquired dengue cases. By 2024, that figure had reached 304. The ECDC's risk assessment for dengue on mainland EU/EEA warns that the increasing geographic range of Aedes albopictus, combined with rising numbers of viraemic travellers returning from endemic regions, creates a growing risk of further outbreaks.

The Vector: Aedes albopictus (Asian Tiger Mosquito)

Understanding the mosquito behind the outbreak is essential to understanding the risk.

A Mosquito Perfectly Adapted to Europe

Aedes albopictus, commonly known as the Asian tiger mosquito, is now established in 16 EU/EEA countries and 369 regions, up from just 114 regions a decade ago. This more than threefold expansion has been driven by several factors:

• Climate change: Rising temperatures and milder winters allow the mosquito to survive in regions that were previously too cold.
• Urban adaptability: Tiger mosquitoes breed in tiny amounts of standing water -- a bottle cap, a discarded tyre, a clogged gutter -- making cities ideal habitats.
• Egg diapause: The species can survive winter as dormant eggs, resuming development when temperatures rise in spring.
• Daytime biting: Unlike many mosquito species that bite primarily at dusk and dawn, Aedes albopictus is an aggressive daytime biter, increasing human contact.

Countries With Established Populations

As of 2025, established tiger mosquito populations exist in Austria, Belgium, Bulgaria, Croatia, Cyprus, France, Germany, Greece, Hungary, Italy, Malta, Portugal, Romania, Slovakia, Slovenia, and Spain, according to ECDC distribution data. Since 2024, new establishments have been confirmed in Cyprus and Slovakia, with range expansions detected in Austria, Belgium, France, Germany and several other countries.

Symptoms of Dengue: What to Watch For

According to WHO, dengue symptoms usually begin 4 to 10 days after infection and last 2 to 7 days.

Common Symptoms

• High fever (40°C / 104°F)
• Severe headache, particularly behind the eyes
• Muscle and joint pain (dengue is sometimes called "breakbone fever")
• Nausea and vomiting
• Skin rash (appearing 3-6 days after fever onset)
• Swollen glands
• Fatigue

Severe Dengue: Warning Signs

About 10% of symptomatic dengue cases develop warning signs that indicate a risk of progression to severe disease, which can be fatal without proper medical care. WHO says these symptoms often come after the fever has gone away and include:

• Severe abdominal pain
• Persistent vomiting
• Rapid breathing
• Bleeding gums or nosebleeds
• Blood in vomit or stool
• Extreme fatigue or restlessness

If you or a family member develops these symptoms after a mosquito bite -- particularly in southern Europe during summer and autumn -- seek medical attention immediately.

Asymptomatic Cases

Most dengue infections cause no symptoms. ECDC estimates that dengue affects about 390 million people a year, with only about 96 million cases causing clinical illness. This means infected individuals can unknowingly serve as a reservoir, allowing local mosquitoes to pick up the virus and transmit it further.

Who Is Most at Risk?

Several factors increase the risk of contracting dengue in Europe:

• Geographic location: Residents of southern France, coastal Spain, Italy (especially the Po Valley, Liguria, and the Adriatic coast), and Greece face the highest risk.
• Outdoor exposure: People who spend time outdoors during daylight hours in areas with established tiger mosquito populations.
• Previous infection: A second dengue infection with a different serotype carries a higher risk of severe disease.
• Age and health: Young children, the elderly, and immunocompromised individuals are more vulnerable to severe outcomes.
• Travellers: Europeans returning from dengue-endemic regions (Southeast Asia, Latin America, the Caribbean) can introduce the virus to areas where competent vectors are present.

Prevention: How to Protect Yourself and Your Family

Personal Protection

• Eliminate standing water around your home: empty plant saucers, clear guttered drains, cover rain barrels, and dispose of any containers that collect water.
• Use physical barriers: Window and door screens, bed nets, and mosquito-proof enclosures remain among the most effective and chemical-free methods of protection.
• Wear protective clothing: Light-coloured, long-sleeved shirts and long trousers reduce exposed skin, particularly during peak biting hours.
• Apply repellents carefully: If using repellents, choose products approved by your national health authority and follow instructions, especially for children.

Community and Municipal Action

• Surveillance programmes: Many EU countries now run mosquito surveillance programmes to track Aedes albopictus distribution and density. Support local efforts by reporting tiger mosquito sightings.
• Integrated vector management: Municipalities in high-risk areas should implement breeding site reduction, larviciding, and public awareness campaigns.
• Blood supply safety: Blood banks in affected regions have implemented screening and deferral policies for dengue.

Vaccination: Limited Options

Dengue vaccines exist (Dengvaxia and Qdenga), but their use in Europe is limited. Qdenga (TAK-003) is authorised by the European Medicines Agency (EMA); Dengvaxia's EU authorisation was withdrawn in 2025. WHO recommends the vaccine only for people aged 6 to 16 in high transmission settings, so it is not part of routine prevention for European residents.

What Does the Future Hold?

The ECDC has been unequivocal: mosquito-borne diseases in Europe are entering a "new normal." The combination of expanding vector populations, increasing global travel, and climate change means that dengue outbreaks in Europe will likely become larger, more frequent, and more geographically widespread.

The 2025 mosquito season set new records for mosquito-borne disease transmission in Europe, and ECDC warns that transmission seasons are becoming longer and more intense. For families, businesses, and municipalities across the continent, proactive protection is no longer optional -- it is essential.

Frequently Asked Questions

Can you catch dengue in Europe?

Yes. Locally acquired dengue cases have been confirmed in France, Spain, and Italy since 2022, with 304 cases reported in 2024 alone.

Is there a dengue vaccine available in Europe?

Qdenga (TAK-003) is authorised in the EU, but WHO recommends it only for people aged 6 to 16 in high transmission settings. Protection through mosquito bite prevention remains the primary strategy.

What time of year is dengue risk highest in Europe?

The risk is highest in the warm months, when Aedes albopictus is active and temperatures are highest, and ECDC reports that transmission seasons are becoming longer and more intense.

Can dengue be fatal?

Yes. Severe dengue can be fatal, though mortality is low when proper medical care is available. Seek immediate medical attention if you experience warning signs after a febrile illness during mosquito season.

About Mosticare: Mosticare develops chemical-free mosquito protection solutions for homes, businesses, and communities across Europe. Our mission: a green, mosquito-free life for every European. Learn more